These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11549802)

  • 1. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
    Brouard MC; Prins C; Mach-Pascual S; Saurat JH
    Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stevens-Johnson syndrome after treatment with STI571: a case report.
    Hsiao LT; Chung HM; Lin JT; Chiou TJ; Liu JH; Fan FS; Wang WS; Yen CC; Chen PM
    Br J Haematol; 2002 Jun; 117(3):620-2. PubMed ID: 12028031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
    Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
    Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous reactions to STI571.
    Brouard M; Saurat JH
    N Engl J Med; 2001 Aug; 345(8):618-9. PubMed ID: 11529225
    [No Abstract]   [Full Text] [Related]  

  • 5. Pityriasis rosea associated with imatinib (STI571, Gleevec).
    Konstantopoulos K; Papadogianni A; Dimopoulou M; Kourelis C; Meletis J
    Dermatology; 2002; 205(2):172-3. PubMed ID: 12218236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
    Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
    Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
    [No Abstract]   [Full Text] [Related]  

  • 7. A patient of chronic myelogenous leukemia developing painful rash on feet.
    Kumar P; Das NK; Sil A; Chakrabarti P
    J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
    [No Abstract]   [Full Text] [Related]  

  • 8. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
    Schwarz M; Kreuzer KA; Baskaynak G; Dörken B; le Coutre P
    Eur J Haematol; 2002 Oct; 69(4):254-6. PubMed ID: 12431246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy].
    Le Nouail P; Viseux V; Chaby G; Billet A; Denoeux JP; Lok C
    Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):686-8. PubMed ID: 17053739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
    Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
    J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
    Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
    Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate-induced pseudoporphyria in two children.
    Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
    Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
    Park MA; Volcheck GW; Guarderas JC
    Allergy Asthma Proc; 2004; 25(5):345-7. PubMed ID: 15603208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications for imatinib mesylate therapy and clinical management.
    Guilhot F
    Oncologist; 2004; 9(3):271-81. PubMed ID: 15169982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec).
    Drummond A; Micallef-Eynaud P; Douglas WS; Hay I; Holyoake TL; Drummond MW
    Br J Haematol; 2003 Mar; 120(5):911-3. PubMed ID: 12614232
    [No Abstract]   [Full Text] [Related]  

  • 18. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
    Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
    Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
    [No Abstract]   [Full Text] [Related]  

  • 19. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
    Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
    Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia.
    Scott AD; Lee M; Kubba F; Chu A
    Clin Exp Dermatol; 2015 Dec; 40(8):926-7. PubMed ID: 25266712
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.